Objectives: Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential antiobesity therapy, but little is known about its pancreatic safety. The aim of the study was to investigate the acute effect of oxyntomodulin and other proglucagonderived peptides on the rat exocrine pancreas.
P
roglucagon-derived peptide glucagon-like peptide 1 (GLP-1) receptor agonists, such as the Food and Drug Administrationapproved exenatide and liraglutide, are widely used in the treatment of type 2 diabetes because of their ability to induce glucose-stimulated insulin secretion, also known as the incretin effect, as well as their beneficial weight-lowering properties. Pancreatic safety became a subject of debate when a number of case reports linked the use of incretin therapies to pancreatitis. Subsequently, a number of postmarketing studies were published supporting this association, [1] [2] [3] [4] [5] [6] and a histological study of human pancreata from organ donors with type 2 diabetes treated with incretin therapy demonstrated an increase in pancreatic size accompanied with elevated ductal proliferation and dysplasia. 7 However, a number of chronic studies in rodents and nonhuman primates found no association between incretin therapies and pancreatic abnormalities. [8] [9] [10] [11] [12] [13] [14] The discrepancy might be explained by confounding factors such as high-fat diet and type 2 diabetes contributing to the development of pancreatitis, irrespective of the use of incretin-based medications. 15, 16 Indeed, in July 2013, the European Medicines Agency's Committee for Medicinal Products for Human Use and the Food and Drug Administration concluded that the data available did not indicate an increased incidence of pancreatitis with GLP-1 receptor agonists and the benefits of their use in patients with type 2 diabetes outweighed any possible risks. 17 However, GLP-1 analogs are currently undergoing regulatory evaluation for use as weight loss agents in obese people without diabetes, increasing the target population of patients potentially eligible for treatment. 18 Oxyntomodulin is another proglucagon-derived peptide, which acts at both GLP-1 and glucagon receptors. It has been demonstrated to have beneficial effects on energy homeostasis via reduction of food intake and increase in energy expenditure in rodents and in man, and its therapeutic potential in the treatment of obesity is currently being assessed. [19] [20] [21] [22] [23] [24] [25] [26] However, little is known about the pancreatic safety of this peptide.
The aim of the study was to evaluate the acute effect of oxyntomodulin and other proglucagon-derived peptides including GLP-1 and glucagon, as well as the GLP-1 analog exendin-4, on the exocrine pancreas and potentially provide additional information on their safety. To that end, in vivo and in vitro peptideinduced amylase secretion, as well as peptide-induced acinar and ductal proliferation, was assessed in the rat model.
METHODS

Study of Plasma Amylase Release In Vivo
Animals
All animal procedures undertaken were approved by the British Home Office under the UK Animal (Scientific Procedures) Act 1986. Adult male Wistar rats (Charles River Ltd, Margate, Kent, United Kingdom) weighing 300 to 500 g were maintained under controlled temperature (21°C-23°C) and lights (12:12-hour light-dark schedule, lights on at 7:00 A.M.). Animals were fasted for 18 hours before the experiment while allowed ad libitum access to water. described by Christakis et al. 27 A catheter was introduced into the left femoral vein to introduce a 30 nmol bolus injection of peptide. To avoid sample contamination, the route of injection was different to the route of sampling. The dose was based on previous unpublished studies performed in the laboratory to achieve detectable levels of each peptide and is 6.25-fold higher than the average therapeutic dose of exendin-4, to maximize the potential side effect. The procedure length and sampling times were chosen to detect early amylase release post-CCK administration and to cover the maximum time spectrum of potential amylase release in response to peptide injection. Blood samples were collected through another catheter placed in the right jugular vein. The catheters used were polyethylene tubing (internal diameter, 0.46 mm; outside diameter, 0.91 mm) (Instech, Solomon, Pa). The operating time for cannulation of the jugular and femoral vein and the unexpected events were recorded in a database. Glucose levels were measured before and during operation to monitor animal stress. At the end of the experiment, animals were killed by CO 2 inhalation and neck dislocation (Schedule 1 method under the Animals [Scientific Procedures] Act 1986).
Sampling
Two baseline samples were obtained from the jugular vein before peptide injection. Postinjection, a 0.1 mL-sample was obtained every 2 minutes for the first 10 minutes, then at 15 minutes, and every 10 minutes until 50 minutes. Total blood volume withdrawn was within recommended volume limits. Plasma amylase activity was determined using an Amylase assay kit (Abcam, Cambridge, United Kingdom) according to the manufacturer's instructions.
Study of Amylase Secretion In Vitro
The rat pancreatic acinar cell line AR42J was purchased from Sigma-Aldrich. AR42J cells were routinely maintained in RPMI 1640 media, supplemented with 10% foetal bovine serum (FBS), 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM glutamine (Sigma-Aldrich). Cells were incubated with 20 nM dexamethasone for 48 hours before secretion assay to induce CCK responsivity, as described by Logsdon et al. 28 Cells from passage 11 to 18 were used throughout this study and were routinely incubated in a humidified incubator at 37°C with 95% air and 5% CO 2 .
To assess amylase secretion, cells were plated at approximately 10 5 cells/mL onto 24-well plates (500 μL/well) 24 hours before the experiment. Immediately before treatment, cells were washed with 0.1 M phosphate buffered saline. Cells were treated for 50 minutes at 37°C with ascending concentrations of the peptides diluted in serum-free RPMI 1640 media. After this, cells were similarly treated with 10 nM of each investigated peptide and CCK. The dose was in agreement with previously published research. 29, 30 The incubation medium was collected and cells were lysed. Lysates were collected for total amylase content. Amylase secretion was then quantified as a percentage of amylase activity in incubation medium compared with total activity (incubation medium plus lysate) using an Amylase assay kit (Abcam) according to the manufacturer's instructions.
Primary Isolation of Epithelial Pancreatic Duct Cells
Rats were killed using a Schedule 1 method under the Animals (Scientific Procedures) Act 1986. An abdominal midline incision was performed to expose the contents of the abdominal cavity. By displacing the liver superiorly and the intestine inferiorly, the duodenum was accessible. Curved dissecting scissors were used to isolate and dissect the pancreas free from its attachments to the duodenum and the rest of the abdominal organs. The organ was then transferred to a 6-cm tissue culture dish with ice-cold Leibovitz (Gibco, Paisley, United Kingdom). Using a dissecting microscope, the surrounding pancreatic tissue was cleaned away and the duct was transferred in a tube containing 5 mL of collagenase XI (Sigma-Aldrich) solution for 12 minutes. After incubation, the remaining fibroblasts were removed and the treatment is repeated. The biliopancreatic duct in rat is a distinct structure under the dissecting scope, which ensures that it neatly isolated with minimum contamination of surrounding tissue.
The ductal cells were isolated as previously described by Chen et al. 31, 32 To dissociate ductal cells from the extracellular matrix, the ducts were incubated with dispase solution (SigmaAldrich). To dissociate the duct into cellular aggregates, it was subjected to a series of trypsinization steps, each one stopped by adding 0.5 mL of ice-cold FBS. The collected fractions were then centrifuged and the resulting pellet was resuspended in pancreatic medium (1:1 Hams F12/DMEM, 100 ng/mL cholera toxin, 100 μg/mL soybean trypsin inhibitor, 20% FBS, penicillin 100 IU/mL, and streptomycin 100 mg/mL) plated in MaxGel ECM (Sigma-Aldrich) matrix coated wells in 6-well plates and incubated at 37°C and at 5% CO 2 .
RNA Extraction and Quantitative Polymerase Chain Reaction in AR42J and Ductal Cells
Cells were cultured 2 hours postisolation to ensure maximum viability and replication detection, in the presence or absence of 10 nM of each peptide for 18 hours. Medium was changed every 9 hours. Peptides were diluted in RPMI 1640 (AR42J) or pancreatic (ductal) medium, supplemented with 2% FBS. Total RNAwas isolated from AR42J cells using TRI Reagent (Sigma-Aldrich) by referring to the manufacturer's protocol. 1-Bromo-3-chloropropane (Sigma-Aldrich) was added to precipitate the total RNA and the extracted RNA pellet was then washed with 75% ethanol. RNA was purified using PureLink RNA kit and DNA was digested from total RNA using PureLink DNase (Thermo Fisher Scientific, Paisley, United Kingdom). The purified RNA was dissolved in RNase and DNase free distilled water (Thermo Fisher Scientific) and was immediately stored at −80°C until further analysis.
Complementary DNA was synthesized from total RNA with High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the protocol recommended by the manufacturer. The protocol conditions were 10 minutes at 25°C for primer annealing, 120 minutes at 37°C for reverse transcription, and 5 minutes at 85°C. Quantitative Polymerase Chain Reaction (PCR) analysis was used to quantify the expression level of proliferation marker Ki-67. For the detection of Ki-67, QPCR primers, which crossed a splice junction, were designed using Primer Express (Invitrogen, Paisley, United Kingdom; Table 1 ). The expression levels were measured using a 7500 Fast Real-Time PCR System (Applied Biosystems, Paisley, United Kingdom). The reaction mixture contained 6 μL of Fast SYBR Green Master Mix (Invitrogen), 0.35 μL of each primer (10 μM, Thermo Fisher Scientific), 3 μL of water, and 2 μL of cDNA in a final volume of 12 μL. Samples were amplified in duplicates. The reaction was started with 2 minutes at 50°C followed by the activation and predenaturation step at 95°C for 10 minutes. The reaction run consisted of 40 cycles comprising 15 seconds at 95°C and 1 minute at 60°C.
Data Analysis
Data are presented as mean (SEM). All reported P values were based on 2-sided tests. Student t test with Bonferroni correction was used in all experiments and 1-way analysis of variance with Tukey post hoc test was used to compare amylase secretion levels of peptide-treated AR42J cells against untreated control group. Ki-67 mRNA data were normalized against β-actin levels.
The analytical method used was 2(−Delta Ct). The level of statistical significance was set at a P value of less than 0.05. Prism 5.01 (GraphPad Software Inc, San Diego, Calif ) statistical software was used for all statistical analysis.
RESULTS
Study of Amylase Secretion In Vivo
A small percentage of amylase that is released in the gut leaks into the bloodstream and its concentration can be used as indicator of pancreatitis. To assess any pathogenic effect of peptides on the exocrine pancreas, rats were infused with GLP-1, exendin-4, glucagon, or oxyntomodulin, and plasma amylase levels were determined at regular time intervals. Cholecystokinin was used as a positive control at a 2.4 nmol/rat dose that could induce significant amylase secretion. The generated curve is used as a comparison in Figures 1 and 2 . Rats treated with CCK demonstrated an almost 2-fold increase in plasma amylase during the 50-minute postinjection period (Figs. 1A, B) . Cholecystokinin increased plasma amylase significantly from 30 minutes onward compared with time 0 (P < 0.01), reaching approximately 18.00 (0.70) U/L. Plasma amylase concentration did not increase post-GLP-1, glucagon, oxyntomodulin, or exendin-4 intravenous injection, compared with basal amylase and vehicle controls. No significant increase in plasma amylase was observed after treatment with the rest of the peptides and the vehicle as amylase levels reached approximately 12.00 (0.21) U/L throughout the 50 minutes of sampling (Figs. 1A, B) . Average basal amylase was 10.50 (0.39) U/L for all groups (n = 4-5).
The effect of each peptide on plasma amylase levels given in combination with CCK was assessed. Coadministration of GLP-1, exendin-4, and glucagon with CCK did not inhibit plasma amylase compared with CCK alone ( Fig. 2A) , with plasma amylase levels increasing from 9.8 (0.37) to 17.52 (0.94) U/L for all groups (n = 4-5). However, oxyntomodulin suppressed CCKinduced amylase release by approximately 3.4 (0.5) U/L on average, when coadministered with CCK (Fig. 2B , n = 5, P < 0.01). Significant inhibition was achieved both in the beginning of sampling at 6 and 8 minutes and the end at 30 and 50 minutes. Pancreas
Study of Amylase Secretion In Vitro
AR42J cells, an in vitro model of the exocrine pancreas, were treated with GLP-1, glucagon, oxyntomodulin, exendin-4, and CCK. Total amylase and secreted amylase levels were measured after 50 minutes of incubation. Treatment of AR42J cells with CCK, a known stimulant of amylase release, resulted in a doseresponsive secretion of amylase, reaching 28% of total amylase activity in 50 minutes (Fig. 3 , n = 5, P < 0.001). The GLP-1, exendin-4, glucagon, and oxyntomodulin did not induce amylase secretion at any of the doses tested, because amylase levels remained stable at 13.8 (0.45%) of total, the same as untreated cells. Coadministration of CCK (1 nM) with each peptide (10 nM) resulted in a nonsignificant trend of an inhibition of CCK-induced amylase secretion (Fig. 4) .
Cell Proliferation in AR42J and Biliopancreatic Ductal Cells
Existence of GLP-1 and glucagon receptors on AR42J and biliopancreatic ductal cells was confirmed by competitive receptor affinity studies (data not shown). To determine whether the test peptides had an effect on the rate of cellular proliferation, AR42J and ductal cells were treated with 10 nM of GLP-1, glucagon, oxyntomodulin, and exendin-4 for 18 hours. After treatment, mRNA was extracted and the level of proliferation marker Ki-67 was analyzed using quantitative PCR (Figs. 5A, B) . Quantitatively, compared with the untreated control cells, the test peptide did not cause a significantly higher expression of Ki-67 (P > 0.05).
DISCUSSION
Our experiments focused on 4 peptides, which have been identified as potential therapeutic agents for the treatment of obesity and type 2 diabetes, with regard to pancreatic safety. A number of preclinical chronic safety studies have been completed in rodents and nonhuman primates to investigate findings of incretin peptides and DPP-IV long term. However, relatively little is known about the actions of incretin peptides on the exocrine pancreas. Incretins have been hypothesized to cause pancreatic ductal and acinar cell hyperplasia and inflammation in the exocrine pancreas. 7, 33, 34 On the other hand, glucagon has been previously suggested to inhibit gastric release, a fact that made it a potential peptide for the treatment of pancreatitis in the past. 35 Amylase plasma concentration increase in pancreatitis is a result of pancreatic enzyme leakage from damaged acinars. In a CCK-induced pancreatitis model in rat, hyperamylasemia was detected 30 minutes posttreatment, whereas acinar damage and pancreatic edema was observed after 60 minutes. 36 Here, we demonstrated no change in amylase release in response to administration of GLP-1, glucagon, exendin-4, and oxyntomodulin, alone, in vivo and in vitro. Similarly, GLP-1, glucagon, and exendin-4 coadministration with CCK did not mitigate against the CCKinduced increase in amylase concentration. However, coadministration of oxyntomodulin and CCK caused a significant inhibition of CCK-induced plasma amylase release in vivo, compared with CCK alone.
A number of in vivo studies have been performed, evaluating the effect of constant infusion of GLP-1, glucagon, and oxyntomodulin 2016 in lower doses in direct pancreatic secretion through bile duct cannulation. Investigations have shown that both glucagon and oxyntomodulin are known to inhibit gastric release, with oxyntomodulin being 10 times more potent than glucagon in this regard, potentially because of its tissue specificity at the gastrointestinal tract, compared with glucagon, which is more specific to the liver. 30, 37, 38 In previous studies in the anesthetized rat, basal pancreatic secretion could not be inhibited by oxyntomodulin infusion, yet when stimulated with a CCK agonist, pancreatic secretion levels decreased. During these studies, an oxyntomodulin effect through vagal afferents was hypothesized, as in physiologic doses of CCK8, afferent messages transmitted in the central nervous system were produced before the observation of an efferent vagal transmission to the rat pancreas. 39 It has been suggested that a possible mechanism of this oxyntomodulin function is through the activity of gastropancreatic intrinsic nerves or by preganglionic inhibition of excitatory vagal fibers via the central nervous system. 30, 40 Nonetheless, the exact mechanism through which oxyntomodulin inhibits CCK8-induced pancreatic secretion, whereas glucagon does not, remains unclear. This study confirmed the inhibitory function of oxyntomodulin, previously shown in overall gastric secretion, and cross-examined whether this effect extends to GLP-1 and exendin-4 using plasma amylase measurement.
Akalestou et al
It has previously been shown that pancreatic ductal cell proliferation is elevated in both obese and diabetic patients, which can predispose pancreatitis, possibly because of the buildup of excessive fat in pancreatic tissue, resulting in β-cell apoptosis and inflammation. 34 Because β-cell numbers decrease in type 2 diabetes, it has been suggested that islet regeneration is attempted through duct-related progenitors and proliferation rate is enhanced by GLP-1, causing blockages in the pancreatic duct, 41 potentially through phosphorylation of cAMP response element-binding protein and stimulation of mitogen-activated protein kinases pathway, 33 whereas Immediate Early Genes egr-1 and c-fos were also investigated. 8 Nonetheless, in this work, GLP-1 and exendin-4 did not increase pancreatic acinar or ductal cell proliferation rate when compared with untreated cells during the course of 18 hours.
AR42J cells are currently the only cell line that maintains a number of normal pancreatic acinar cell characteristics, when in culture, such as the synthesis and secretion of digestive enzymes protein expression and receptor expression similar to pancreatic acinars. AR42J cells, used in this study, are derived from a chemically induced exocrine pancreatic tumor; therefore, these are not grown from a single clone and can present response differences. 42 Even so, our results are in agreement with previous studies that used both AR42J and isolated rat acini treated with GLP-1 and expand the investigated effect to oxyntomodulin and glucagon. 29, 30, 43 Taken together, our results indicate that GLP-1 and exendin-4 do not have an acute effect on exocrine pancreatic release, in the in vivo and in vitro models tested. Further studies in diabetic or obese rat models should be performed to determine whether failure to observe an acute effect persists in these disease states. Our finding that oxyntomodulin protects against the CCKinduced increase in the appearance of pancreatic enzymes in the blood in vivo supports a favorable pancreatic safety profile for this peptide, because it could be protective in cases of type 2 diabetes-induced pancreatitis. The fact that this observation was not replicated in vitro might suggest that the peptide might not be damaging or acting directly on acinar cells, with one possibility being this effect is mediated via vagal innervation. 30 Because oxyntomodulin is a dual GLP-1/glucagon receptor agonist, the finding that neither GLP-1 nor glucagon alone produced this effect is interesting and merit further investigation. Furthermore, longer-term studies need to be performed to further understand the effect of this peptide on pancreatic exocrine tissue and will be critical if this peptide is to be used as a weight loss agent in the future.
Because the use of GLP-1 receptor agonists for the treatment of obesity has been licensed, 18 it is likely that there will be a rapid increase in the number of patients taking this class of medication. Although numerous long-term safety pharmacology studies have been completed and pharmacovigilance systems are in place, questions remain regarding the pancreatic safety of this drug class. Dual GLP-1 and glucagon receptor agonists are also underdevelopment as obesity treatments. In this study, we found an inhibitory effect of oxyntomodulin on the CCK-induced increase in the appearance of pancreatic enzyme in blood, which might support that it could be useful in the treatment of diabetic obese patients, because it can have a protective effect against diabetes-induced pancreatic inflammation, in addition to weight loss induction.
